Prognostic and Predictive Model of the Log Odds of the Negative Lymph Node/T Stage Ratio in Resectable Gastric Adenocarcinoma Patients

J Gastrointest Surg. 2022 Aug;26(8):1743-1756. doi: 10.1007/s11605-022-05408-8. Epub 2022 Jul 14.

Abstract

Purpose: There are few reports on disease-specific survival (DSS) prediction systems for resected gastric cancer (GC) patients. The aim of this study was to create a nomogram based on the log odds of the negative lymph node/T stage ratio (LONT) for individual risk prediction.

Methods: We applied the Surveillance, Epidemiology, and End Results (SEER) Program database released in 2021 to screen GC patients from 2010 to 2015. Using a competitive risk model, we plotted the cumulative risk curve of variables for gastric cancer-specific death and death from other causes at each time point. According to the minimum BIC, we constructed and assessed a nomogram for the 12-month, 36-month, and 60-month cumulative mortality probabilities assessed by time-dependent ROC curves (time-AUCs), the C-index, Brier scores, decision curve analysis (DCA), and calibration curves.

Results: A total of 3895 patients were ultimately included and randomly assigned to two sets: the training set (n = 2726, 70%) and the validation set (n = 1169, 30%). The LONT was a remarkable independent predictor of gastric cancer-specific death (high versus low: 0.705, 95% CI 0.524-0.95, p = 0.021). The variables selected based on the minimum BIC were as follows: location, AJCC, AJCC.T, AJCC.N, radiotherapy, LONT.cat, and chemotherapy. According to the time-AUC, C-index, Brier score, DCA, and calibration curves, the nomogram risk score had excellent survival prediction ability for DSS.

Conclusions: A low LONT was associated with a high cumulative incidence of DSS. A prognostic nomogram model based on the LONT could effectively predict DSS for resectable GC patients.

Keywords: Gastric cancer; Negative lymph nodes; Negative lymph nodes/T stage; Nomogram; Prognosis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma* / pathology
  • Humans
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Neoplasm Staging
  • Nomograms
  • Prognosis
  • SEER Program
  • Stomach Neoplasms* / pathology